Image For Activity Cover
The Lead Episode 59: Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials
Description

Jason T. Jacobson, MD, FHRS, Westchester Medical Center-New York Medical College, is joined by William H. Sauer, MD, FHRS, Brigham and Women's Hospital, and Christian Thomas Ruff, MD, Brigham and Women's Hospital to discuss a meta-analysis of the 2 recent randomized controlled trials of oral anticoagulation vs aspirin and placebo for atrial high rate episodes detected by cardiac implanted electronic devices. The trials included are NOAH-AFNET6 and ARTESIA, which reported discordant results. When analyzed together, this study shows that anticoagulation does decrease embolic risk in this patient population.

Learning Objectives
  • Recognize that patients with device-detected atrial fibrillation may benefit from oral anticoagulation.
Article Authors and Podcast Contributors
Article Authors
William F. McIntyre, Alexander P. Benz, Nina Becher, Jeffrey S. Healey, Christopher B. Granger, Lena Rivard, A. John Camm, Andreas Goette, Antonia Zapf, Marco Alings, Stuart J. Connolly, Paulus Kirchhof, Renato D. Lopes

Podcast Contributors
Jason T. Jacobson, MD, FHRS, Westchester Medical Center-New York Medical College
Christian Thomas Ruff, MD, Brigham and Women's Hospital
William H. Sauer, MD, FHRS, Brigham and Women's Hospital

Faculty and Disclosures

All relevant financial relationships have been mitigated.


Host Disclosure(s):
J. Jacobson: Honoraria/Speaking/Consulting: American College of Cardiology, Zoll Medical Corporation, Research: Abbott, Phillips, Stock, Privately Held: Atlas 5D

Contributor Disclosure(s):
C. Ruff: Honoraria/Speaking/Consulting: Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals, Research: Daiichi, MedImmune
W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
S. Colbert: No relevant financial relationships with ineligible companies to disclose.
Summary
Availability: On-Demand
Expires on Apr 25, 2027
Cost: FREE
Credit Offered:
No Credit Offered
Recommended
  Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy | Cookie Declaration | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
 
Android App Download IOS App Download Powered By